BARDA awarded Scynexis a $214 million contract to develop SCY-247, an investigational treatment for serious drug-resistant fungal infections. The funding supports the program’s advancement, adding to BARDA’s role in de-risking late-stage translation for high-need antimicrobials and expanding the profile of antifungal candidates beyond academic and early clinical visibility.